Assessing recent recurrence after hepatectomy for hepatitis B-related hepatocellular carcinoma by a predictive model based on sarcopenia

Figure 2 Predicting the probability of 1- and 2-yr recurrence-free survival in hepatocellular carcinoma patients at 1- and 2-yr after hepatectomy using a visualized SAMD model's nomogram (SAMD model: Sarcopenia, alpha-fetoprotein ≥ 40 ng/mL, the maximum diameter of tumor > 5 cm, and hepatitis B virus level ≥ 2000 IU/mL). A: Calibration plots of predicted 1- and 2-yr recurrence-free survival based on the cox regression model in the training and validation cohorts; B: Training cohort (a and b); validation cohort (c and d). AFP: Alpha-fetoprotein; RFS: Recurrence-free survival; HBV: Hepatitis B virus; SAMD: Based on the sarcopenia to assess the recurrence-free survival model of hepatectomy with hepatitis B-related liver cancer disease.